Carboplatin-Teva

Country of origin: Israel, Teva Pharmaceutical Companies/Pharmachemi Netherlands
Pharm-Group: Alkylating agents, platinum derivatives

Manufacturers: Teva Pharmaceutical Enterprises Ltd. (Israel), Teva Pharmaceutical Enterprises/Pharmachemi (Netherlands)
International name: Carboplatin
Synonyms: Blastocarb, Carboplatin, Carboplatin-Lance, Carboplatin-Ebewe, Kemocarb, Paraplatin, Cycloplatin
Dosage forms: lyophilized powder for the preparation of injection solution, solution for intravenous injection 10 mg/ml, lyophilized powder for the preparation of injection solution 50 mg, lyophilized powder for the preparation of injection solution 150 mg

Composition: Active substance - Carboplatin.

Indications for use: Ovarian cancer, malignant testicular tumors, small cell lung cancer, squamous cell cancer of the head and neck, cancer of the cervix and uterine body, breast, soft tissue sarcoma.

Contraindications: Hypersensitivity (including to other drugs containing platinum), severe renal impairment, myelosuppression, pregnancy, lactation, clinical signs of bleeding.

Side effects: Myelosuppression - thrombocytopenia, leukopenia, anemia, increased susceptibility to infectious diseases, bleeding; Gastrointestinal disorders - nausea, vomiting, diarrhea, change in taste; decreased hearing acuity, paresthesia, impaired liver function, alopecia, increased creatinine and urea levels, hypomagnesemia, hypokalemia, hypocalcemia, fever, chills, allergic reactions.

Interaction: Pharmaceutically incompatible with aluminum salts. Strengthens (mutually) the nephrotoxicity of propranolol, aminoglycosides, diazoxide.

Overdose: No information.

Special instructions: It is necessary to conduct weekly monitoring of the cellular composition of the blood and laboratory parameters characterizing the function of the liver and kidneys.

Literature: Encyclopedia of Medicines, 2003.